Chutes & Ladders: Merck realigns division chiefs; focuses on vaccines

Merck has realigned the positions of some of its top division chiefs as it focuses on several areas, especially the development of vaccines. Margaret McGlynn is being hustled into the president's spot of Merck Vaccines as the drug giant spurs the development of four late-stage vaccines. CFO Judy Lewent will also take on additional responsibilities in strategic planning.

- read this report from Newsday for more

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .